Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Chiara Lazzari1, Alessandra Bulotta1, Monika Ducceschi1
1Department of Oncology, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute , Milan , Italy.
Abstract:
Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who depend on oncogenic molecular alterations for their malignant phenotype. Despite the survival improvement achieved with first-line chemotherapy, about 30% of patients do not obtain a tumor response. Moreover, those patients, initially sensitive to treatment, acquire resistance and develop tumor progression after a median of about 5 months. Approximately 60% of the patients progressing from first-line chemotherapy receive further systemic treatment in the second-line setting. Moreover, new options have emerged in the second-line armamentarium for the treatment of patients with NSCLC, including immune checkpoint inhibitors and antiangiogenic agents. The current review provides an overview on the clinical studies that gained the approval of chemotherapy agents (docetaxel and pemetrexed) and epidermal growth factor receptor gene-tyrosine kinase inhibitors as second-line treatment options for NSCLC patients, not carrying molecular alterations.
Insights
For non-small cell lung cancer (NSCLC) patients without molecular alterations, chemotherapy agents like docetaxel and pemetrexed, along with epidermal growth factor receptor gene-tyrosine kinase inhibitors, are approved second-line treatments. These offer new options for patients progressing after initial chemotherapy.
Area of Science:
- Oncology
- Medical Oncology
- Cancer Therapeutics
Background:
- Innovative therapies have improved outcomes for non-small cell lung cancer (NSCLC) patients with specific molecular alterations.
- However, approximately 30% of NSCLC patients do not respond to first-line chemotherapy, and many develop resistance within months.
- A significant portion of patients progressing on first-line therapy receive second-line systemic treatment.
Purpose of the Study:
- To review clinical studies on approved second-line treatment options for NSCLC patients.
- Focus on chemotherapy agents and tyrosine kinase inhibitors for patients without targetable molecular alterations.
Main Methods:
- Review of clinical studies evaluating second-line therapies in NSCLC.
- Analysis of approved chemotherapy agents (docetaxel, pemetrexed) and EGFR TKIs.
- Focus on patient populations without specific oncogenic molecular alterations.
Main Results:
- Docetaxel and pemetrexed are approved chemotherapy agents for second-line NSCLC treatment.
- Epidermal growth factor receptor (EGFR) gene-tyrosine kinase inhibitors are also established second-line options.
- These agents provide therapeutic alternatives for patients lacking specific molecular targets.
Conclusions:
- Chemotherapy agents and EGFR TKIs represent key second-line treatment options for NSCLC patients without targetable mutations.
- These therapies address the unmet need for patients who progress after initial chemotherapy.
- The review highlights approved agents for this specific NSCLC patient subgroup.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...